Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The immune system represents a significant barrier to successful gene therapy with adeno-associated viral (AAV) vectors. In particular, adaptive immune responses to the viral capsid or the transgene product are of concern. The sensing of AAV by toll-like receptors (TLRs) TLR2 and TLR9 has been suggested to play a role in innate immunity to the virus and may also shape subsequent adaptive immune responses. Here, we investigated the functions of TLR2, TLR9 and the downstream signaling adaptor MyD88 in antibody and CD8+ T-cell responses. Antibody formation against the transgene product occurred largely independently of TLR signaling following gene transfer with AAV1 or AAV2 vectors, whereas loss of signaling through the TLR9-MyD88 pathway substantially reduced CD8+ T-cell responses. In contrast, MyD88 (but neither of the TLRs) regulated antibody responses to capsid. B cell-intrinsic MyD88 was required for the formation of anti-capsid IgG2c independently of vector serotype or route of administration. However, MyD88-/- mice instead produced anti-capsid IgG1 that emerged with delayed kinetics but nonetheless completely prevented in vivo readministration. We conclude that there are distinct roles for TLR9 and MyD88 in promoting adaptive immune responses to AAV-mediated gene transfer and that there are redundant MyD88-dependent and MyD88-independent mechanisms that stimulate neutralizing antibody formation against AAV.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alternatively, some studies have reported that anti-AAV capsid immunoglobulin (Ig) G2 antibody production is not dependent on any specific TLR alone but on the intrinsic MyD88 signaling in B cells [30, 43].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [30]
In the citing paper
“TLR-mediated signaling, triggering innate immunity and subsequent activation of adaptive immune response, is an important AAV sensing mechanism [30].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [30]
In the citing paper
“In addition, other studies have shown that self-complementary AAV (scAAV) vectors exhibited an increased innate immune response to the transgene compared with single-stranded AAVs (ssAAVs), possibly due to enhanced activation of the TLR9/MyD88 signaling cascade [30, 44, 45].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [30]
In the citing paper
“Studies have shown that intracellular TLR9 contributes to immune responses against the transgene and capsid [30, 34, 35].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [30]
In the citing paper
“Initial innate immune detection of AAV vectors occurs via toll-like receptor 9 (TLR9) (7, 8).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [7]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Jayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72
Self-citationRetractedManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
He, B., Santamaria, R., Xu, W., Cols, M., Chen, K., Puga, I., Shan, M., Xiong, H., Bussel, J. B., Chiu, A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1914 · Cited by 349
Integration of B cell responses through Toll-like receptors and antigen receptors
Rawlings, D. J., Schwartz, M. A., Jackson, S. W., & Meyer-Bahlburg, A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3190 · Cited by 339
Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“TLR9-MD88 signaling and T1 IFN production can have amodulating effect on antibody formation against capsid or transgene product but is not as strictly required as for CD8 T cell priming (although MyD88 has an intrinsic role in B cells in Th1-dependent antibody class switching).(68,70,71) This is in contrast to CD4 T h…”
BackgroundSelf-citationAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“TLR9 engagement has been associated with enhanced capsid antigen presentation into major histocompatibility complex (MHC) class I and subsequent capsid-specific CD8 T cell activation.(44,52,57) Also, the MyD88 (myeloid differentiating factor 88)-TLR9 pathway has been shown to mediate the induction of immune responses…”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“Antigen presentation through MHC class I expressed onto hepatocytes has been associated with incomplete CD8+ T cell activation and increased exhaustion and apoptosis (89, 93, 94, 100–103).”
BackgroundInfluentialOvercoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
“This increase was also attributed to an amplified activation of the TLR9/MyD88 pathway (34).”
BackgroundAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“any specific TLR alone but on the intrinsic MyD88 signaling in B cells [30, 43].”
BackgroundInfluentialGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
“TLR9 signaling in general is more connected to activation of CD8+ T cells than to B cell responses against AAV.13,15,18,19 This pathway appears be uniquely responsible for inducing capsid-specific CD8+ T cells, while an alternative activation signal via TLR4 cannot compensate for the lack of TLR9.”
InfluentialSelf-citationSuperior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114
Self-citationImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104
“In mice, anti-AAV antibody production seems to depend on the B cell–intrinsic MyD88 signaling pathway (21, 30).”
BackgroundImmune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
“Complimentary studies in mice deficient in intrinsic components of innate recognition and activation (TLR2 / , TLR4 / , TLR7 / , TLR8 / , TLR9 / , and MyD88 / ) have revealed critical sensors and immune cells needed for Th1 antibody responses to AAV vectors.(19,20) In terms of capsid antibody responses, the only diffe…”
BackgroundSelf-citationErtl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
Self-citationMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
“Proinflammatory cytokines facilitate immune cell recruitment and activation(39) and stimulate CD8 T cell responses.(40) Zhu et al demonstrated that the TLR9-MyD88–induced production of type I interferon is essential for the activation of the CD8 T cell response to the capsid and transgene-encoded product and is associ…”
BackgroundEffect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
“Initial innate immune detection of AAV vectors occurs via toll-like receptor 9 (TLR9) (7, 8).”
BackgroundSelf-citationShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
“Some of these may also apply to CD8+ T cell responses against the transgene product, which were also found to be TLR9-dependent.24,26 There are overlapping but also distinct requirements for B and T cell activation, so that for instance blockage of T1 IFN signaling prevents CD8+ T cell but not B cell activation agains…”
BackgroundSelf-citationChowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Gene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
“antibody formation overall is modest, as antibodies form even in TLR9 knockout mice [37].”
BackgroundInfluentialSelf-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“• vector capsid (55)/genome (51, 58)/dsRNA (64) sensing”
BackgroundInfluentialBiswas, M., Sarkar, D., Kumar, S. R. P., Nayak, S., Rogers, G. L., Markusic, D. M., Liao, G., Terhorst, C., & Herzog, R. W. (2015) · Blood · doi:10.1182/blood-2014-09-599266 · Cited by 70
“) injected with 1x10(11) vector genomes (vg)/mouse of scAAV1-CMV-OVA as described.(1) OVA-specific CD8 T cell responses in peripheral blood were quantified by surface labeling with the iTag tetramer/PE-H-2kb OVA(SIINFEKL) from MBL International (Woburn, MA).”
MethodSelf-citationThe Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
Self-citationGross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 65
“In particular, loss of MyD88, a central node for the signaling downstream of Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor pathways, significantly reduced anti-AAV NAb titers (95, 96).”
BackgroundNeuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib, T. Z., & Martin, K. R. G. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1663385 · Cited by 67
Doerfler, P. A., Todd, A. G., Clément, N., Falk, D. J., Nayak, S., Herzog, R. W., & Byrne, B. J. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.103 · Cited by 54
Self-citationHandyside, B., Ismail, A. M., Zhang, L., Yates, B., Xie, L. Y., Sihn, C., Murphy, R., Bouwman, T., Kim, C. K., Angelis, R. D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.001 · Cited by 54
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
“25,39 These mice tend to have delayed antibody formation with altered IgG class switching due to a B cell intrinsic role of MyD88.”
Self-citationHuang, L., Wan, J., Wu, Y., Tian, Y., Yao, Y., Yao, S., Ji, X., Wang, S., Su, Z., & Xu, H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119142 · Cited by 48
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Herzog, R. W., Cooper, M., Perrin, G. Q., Biswas, M., Martino, A. T., Morel, L., Terhorst, C., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.012 · Cited by 39
“Therefore, IgG1 formation against hFIX upon muscle-directed AAV gene transfer is dependent on serotype and vector dose but occurs even in TLR9- and MyD88-deficient mice [39].”
Self-citationUncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
Ertl, H. C. J. (2023) · Drugs · doi:10.1007/s40265-023-01836-1 · Cited by 43
Self-citationTLR9/MyD88/TRIF signaling activates host immune inhibitory CD200 in Leishmania infection
Sauter, I. P., Sotomayor, K. G. M., de Assis, J. B., Sá‐Nunes, A., Torrecilhas, A. C., Staquicini, D. I., Pasqualini, R., Arap, W., & Cortéz, M. (2019) · JCI Insight · doi:10.1172/jci.insight.126207 · Cited by 40
“The importance of MyD88 in TLR9 activation is well known (40), but only TRIF signaling is proposed to respond to high doses of CpG oligodeoxynucleotide (27).”
BackgroundButterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
Self-citationModifying immune responses to adeno-associated virus vectors by capsid engineering
Bentler, M., Hardet, R., Ertelt, M., Rudolf, D., Kaniowska, D., Schneider, A., Vondran, F. W. R., Schoeder, C. T., Delphin, M., Lucifora, J., et al. (2023) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.015 · Cited by 34
“However, there is clear evidence for the importance of MyD88 in B cells for antibody generation.(33,34) Therefore, targeting MyD88 might be more promising than focusing on the inhibition of TLR9.”
BackgroundObstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“There is an emerging picture from mice data that AAV vectors activate the innate immune response through the TLR9 pathway including MyD88, which in turn promotes the adaptive anti-AAV capsid CD8 T cells’ immune response [33-36].”
BackgroundHepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 36
“This leads to maturation of antigen presenting cells and activation of neutrophils, macrophages and natural-killer cells [41, 46–48].”
TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
Kumar, S. R. P., Biswas, M., Cao, D., Arisa, S., Muñoz-Melero, M., Lam, A. K., Piñeros, A. R., Kapur, R., Kaisho, T., Kaufman, R. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.029 · Cited by 31
Self-citationDudek, A. M., & Porteus, M. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660302 · Cited by 32
“As a DNA hairpin with a free DNA end, the ITRs can also be sensed by DNA damage response (DDR) proteins in the nucleus (97).”
BackgroundToll‐Like Receptors and Tissue Remodeling: The Pro/Cons Recent Findings
Micera, A., Balzamino, B. O., Zazzo, A. D., Biamonte, F., Sica, G., & Bonini, S. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25124 · Cited by 31
“These molecules drive positive or negative intracellular regulations, actually representing targets for focused therapies (Akira and Takeda, 2004; Kumar et al., 2009; Rogers et al., 2015).”
BackgroundImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
Self-citationPeeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
Ishibashi, Y., Sung, C. Y. W., Grati, M., & Chien, W. W. (2023) · Hearing Research · doi:10.1016/j.heares.2023.108735 · Cited by 30
“The helper CD4 + T cells also activate B cells for antibody production ( Rogers et al., 2015 ; Sudres et al., 2012 ).”
Chen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
“Our data corroborate previous studies’ findings using C3 [37] and MyD88 mice [34, 36].”
BackgroundResultPreclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
Self-citationRisk mitigation of immunogenicity: a key to personalized retinal gene therapy
Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312818 · Cited by 19
Kaczmarek, R., Piñeros, A. R., Patterson, P. E., Bertolini, T. B., Perrin, G. Q., Sherman, A., Born, J., Arisa, S., Arvin, M. C., Kamocka, M. M., et al. (2023) · Blood · doi:10.1182/blood.2022018937 · Cited by 29
Self-citationImmunology of Retinitis Pigmentosa and Gene Therapy–Associated Uveitis
Yang, P. G., Mustafi, D., & Pepple, K. L. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041305 · Cited by 22
AAV Vectored Immunoprophylaxis for Filovirus Infections
Rghei, A. D., van Lieshout, L. P., Santry, L. A., Guilleman, M. M., Thomas, S. P., Susta, L., Karimi, K., Bridle, B. W., & Wootton, S. K. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5040169 · Cited by 17
“In particular, the AAV DNA genome and capsid are sensed by TLR9 and TLR2, respectively [171,172], and AAV vectors carrying double-stranded genomes show higher immunogenicity relative to those carrying single-stranded genomes [173].”
BackgroundAnchim, A., Raddi, N., Zig, L., Perrieau, P., Goffic, R. L., Ryffel, B., & Benihoud, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00124 · Cited by 16
“MyD88 expressed in B cell could also directly promote isotype switching and affinity maturation as described previously (32, 38).”
MethodDuan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
Self-citationReprogramming human B cells with custom heavy-chain antibodies
Rogers, G. L., Huang, C., Mathur, A., Huang, X., Chen, H.-Y., Stanten, K., Morales, H., Chang, C.-H., Kezirian, E. J., & Cannon, P. M. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01240-4 · Cited by 17
“Protocols were adapted from previously described ELISA protocols 78 .”
Self-citationRedundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer
Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 14
“Mouse plasma was analyzed for OVA-specific IgG2c antibodies as previously published [34,35].”
BackgroundMethodInfluentialSelf-citationEngineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13
Da Rocha, S., Bigot, J., Onodi, F., Cosette, J., Corre, G., Poupiot, J., Fenard, D., Gjata, B., Galy, A., & Neildez-Nguyen, T. M. A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.011 · Cited by 12
“The induction of antibodies to the AAV caspid is dependent upon innate immune activation and involves TLR9-mediated CD4 T cell activation into TH1 effector cells.(24,25) To assess the effects of MnTBAP on the induction of anticapsid antibodies following rAAV gene transfer, we designed a protocol in which the rAAV vect…”
MethodJarvi, N. L., Hofman, K., Venkatesh, A., Gorecki, E., & Balu‐Iyer, S. V. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.006 · Cited by 10
Iroanya, G. I., Subramanyam, P. N., Wells, K. D., & Green, J. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251378524 · Cited by 11
Rghei, A. D., Cao, W., He, S., Lopes, J. A., Zielinska, N., Pei, Y., Thompson, B., Banadyga, L., & Wootton, S. K. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad345 · Cited by 10
Liu, Y., Gan, L. N., Qin, W. Y., Sun, S., Zhu, G., Wu, S., & Bao, W. (2016) · Polish Journal of Veterinary Sciences · doi:10.1515/pjvs-2016-0037 · Cited by 10
Tirap controls Mycobacterium tuberculosis phagosomal acidification
Belhaouane, I., Pochet, A., Chatagnon, J., Hoffmann, E., Queval, C. J., Deboosère, N., Boidin‐Wichlacz, C., Majlessi, L., Sencio, V., Heumel, S., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011192 · Cited by 10
“As a matter of fact, Myd88-independent TLR9 signalling was already reported in other studies [36,37].”
ResultAraujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
“This includes humoral immune responses against the capsid 26,27 and transgene product, 26 with B cell intrinsic MyD88 signaling playing a major role.”
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies
Doshi, B. S., Markmann, C., Novak, N. C., Rojas, S. J., Davidson, R. J., Chau, J. Q., Wang, W., Carrig, S., Rus, C. M., Samelson‐Jones, B. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.003 · Cited by 9
“The innate immune response to AAV is facilitated by toll-like receptor 9 and MyD88 signaling 39,40 followed by activation of CD4 + and CD8 + T cells via antigen presentation on major histocompatibility complexes.”
Adeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist
Jagadisan, B., & Dhawan, A. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12326 · Cited by 9
Ezechukwu, H. C., Adegboye, O. A., Okunowo, W. O., & Emeto, T. I. (2023) · Allergies · doi:10.3390/allergies3020007 · Cited by 7
Abdelhamid, L., & Mazor, R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01127-5 · Cited by 7
“Studies suggest involvement of redundant innate sensors, such as the Toll Like Receptors (TLRs) with TLR9 as the major driver of AAV-immunogenicity, sensing unmethyl-ated CpG motifs on the DNA of the AAV (40, 41), particularly after systemic administration (42).”
Han, J. X., Ng, G. Z., Cecchini, P., Chionh, Y. T., Saeed, M. A., Næss, L. M., Joachim, M., Blandford, L. E., Strugnell, R. A., Colaco, C. A. L. S., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.001 · Cited by 5
“Perhaps related to this mechanism are recent demonstrations that MyD88 is also not essential for the generation of an antibody response against adenoviral capsid protein and bacterial flagellin [40,41].”
BackgroundViral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 7
Gene Therapy for Heart Failure: Impact on Mitochondrial Dysfunction
Blagonravov, M. L., Sklifasovskaya, A. P., Karpov, R. M., Ovechkina, V. S., Andrianova, S. K., Syatkin, S. P., Belousov, V. V., & Mozhaev, A. A. (2026) · Biomedicines · doi:10.3390/biomedicines14020344 · Cited by 2
“Another crucial mechanism is TLR-mediated signaling, primarily via TLR9, which contributes to immune responses against both the transgene and the capsid [106].”
Holtkamp, S., Lagoda, F. R., Lister, A., Harish, P., Kleymann, U., Pesch, T., Soon, C. F., Pirmohamed, M., Naisbitt, D. J., & Trautwein, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450524 · Cited by 3
Ou, Y., Wu, F., He, C., Luo, S., Guo, Z., Zhang, Y., Hu, R., Xu, Y., Tang, X., Zhao, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71194-5 · Cited by 1
Immunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Adeno-associated virus-induced neurotoxicity is prevented by CpG depletion
Dunn, C. E., Carvajal, B. V., Ma, J., Castaneda-Hernandez, G., Nguyen, A. V., Jung, C., Suriano, C. M., & Boulanger, L. M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201703 · Cited by 1
Anchim, A. (2016) · theses.fr (ABES) · doi:10.70675/d10fb830z5afez4e17zb40fz3b23249344dc · Cited by 1
Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma
Ghersa, F., Yung, C., Molina, E., Kuoch, H., Caine, C., Krotova, K. Y., Borgatti, A., & Aslanidi, G. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201282
“…to AAV by observing relative elevation of common inflammatory markers MyD88, TLR9, IFN-γ , TNF-α , and IL-6, previously reported as indicators of AAV infection, 65 with quantitative reverse-transcription PCR (RT-qPCR) performed for PBMCs collected 2 h after vaccination on three tested dogs.”
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
Self-citationManz, J., Woernle, J., Hubbuch, J., Deepak, R., Noack, F., & Huellen, F. (2026) · Viruses · doi:10.3390/v18101158
“Unmethylated CpGs are recognized by TLR9 and trigger inflammation and thus an antiviral response via the MyD88 pathway [13–15].”
Rogers, G. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.19503672 · Cited by 1
Self-citation
Metadata
- Authors
- Rogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W.
- Affiliations
- University of Florida (US)
- Howard Hughes Medical Institute (US)
- The Wistar Institute (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- Journal of Innate Immunity
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 7
- Issue
- 3
- Pages
- 302-314
- ISSN
- 1662-811X (ISSN-L)
- 1662-8128
- PMC
- PMC4417066
- OpenAlex
- W2027049071
- Cited by
- 85
- References
- 41
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 8 · 2023: 16 · 2022: 6 · 2021: 9 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 4 · 2015: 4
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Journal of Innate Immunity (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Florida
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R00HL098692, P01HL078810, R01HL087836)
- National Institute of Allergy and Infectious Diseases (R01AI051390, R01 AI51390, P30AI045008, T32AI007110)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01 HD078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus vectors, TLR9, MyD88, TLR2, adaptive immune response, CD8+ T cells, AAV1, AAV2, neutralizing antibodies
- MeSH terms
- Dependovirus, Animals, Antibody Formation, B-Lymphocytes, Immunoglobulin G, Transduction, Genetic, Mice, Knockout, CD8-Positive T-Lymphocytes, Toll-Like Receptor 9, Mice, Myeloid Differentiation Factor 88, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.